Study population characteristics
| . | Total (n = 316) . | Period 1 (n = 186) . | Period 2 (n = 130) . | P . |
|---|---|---|---|---|
| Age – median (IQR) | 56.0 (43.5-64.0) | 56.0 (42.0-64.0) | 58.5 (47.0-65.0) | .23 |
| < 50 y - n (%) | 106 (33.5) | 65 (35.0) | 41 (31.5) | |
| 50-60 y - n (%) | 93 (29.4) | 57 (30.7) | 36 (27.7) | |
| > 60 y - n (%) | 117 (37.0) | 64 (34.4) | 53 (40.8) | |
| Sex - n (%) | .50 | |||
| Male | 166 (52.5) | 103 (55.4) | 63 (48.5) | |
| Female | 150 (47.5) | 83 (44.6) | 67 (51.5) | |
| Disease - n (%) | .85 | |||
| Acute myeloid leukemia | 132 (41.8) | 74 (39.8) | 58 (44.6) | |
| Myelodysplastic syndrome | 58 (18.4) | 34 (18.3) | 24 (18.5) | |
| Acute lymphoblastic leukemia | 48 (15.2) | 27 (14.5) | 21 (16.2) | |
| Lymphoma | 24 (7.6) | 16 (8.6) | 8 (6.2) | |
| Primary/secondary myelofibrosis | 22 (7.0) | 14 (7.5) | 8 (6.2) | |
| Others | 32 (10.1) | 21 (11.3) | 11 (8.5) | |
| Second transplant - n (%) | 21 (6.6) | 16 (8.6) | 5 (3.8) | .095 |
| Donor type - n (%) | .044 | |||
| Matched sibling | 66 (20.9) | 42 (22.6) | 24 (18.5) | |
| Matched unrelated | 155 (49.1) | 84 (45.2) | 71 (54.6) | |
| Mismatched unrelated | 42 (13.3) | 21 (11.3) | 21 (16.2) | |
| Haploidentical | 53 (16.8) | 39 (21.0) | 14 (10.8) | |
| Donor CMV serostatus - n (%) | .43 | |||
| Positive | 224 (70.9) | 135 (72.6) | 89 (68.5) | |
| Negative | 92 (29.1) | 51 (27.4) | 41 (31.5) | |
| Stem cell source - n (%) | .066∗ | |||
| Bone marrow | 141 (44.6) | 92 (49.5) | 49 (37.7) | |
| Peripheral blood stem cell | 171 (54.1) | 94 (50.5) | 77 (59.2) | |
| Cord blood | 4 (1.3) | 0 (0) | 4 (3.1) | |
| Conditioning regimen - n (%) | .56 | |||
| Myeloablative | 147 (46.5) | 84 (45.2) | 63 (48.5) | |
| Reduced intensity | 169 (53.5) | 102 (54.8) | 67 (51.5) | |
| Total body irradiation - n (%) | 62 (19.6) | 34 (18.3) | 28 (21.5) | .47 |
| GVHD prophylaxis - n (%) | .14 | |||
| Cyclosporin A + methotrexate | 229 (72.5) | 129 (69.4) | 100 (76.9) | |
| Cyclosporin A + MMF | 87 (27.5) | 57 (30.6) | 30 (23.1) | |
| In vivo T-cell depletion - n (%) | 219 (69.3) | 127 (68.3) | 92 (70.8) | .64 |
| Antithymocyte globulin | 155 (49.1) | 82 (44.1) | 73 (56.2) | |
| Post-transplant cyclophosphamide | 64 (20.3) | 45 (24.2) | 19 (14.6) | |
| CMV risk score - n (%) | .79 | |||
| Low-risk | 156 (49.4) | 93 (50.0) | 63 (48.5) | |
| High-risk | 160 (50.6) | 93 (50.0) | 67 (51.5) |
| . | Total (n = 316) . | Period 1 (n = 186) . | Period 2 (n = 130) . | P . |
|---|---|---|---|---|
| Age – median (IQR) | 56.0 (43.5-64.0) | 56.0 (42.0-64.0) | 58.5 (47.0-65.0) | .23 |
| < 50 y - n (%) | 106 (33.5) | 65 (35.0) | 41 (31.5) | |
| 50-60 y - n (%) | 93 (29.4) | 57 (30.7) | 36 (27.7) | |
| > 60 y - n (%) | 117 (37.0) | 64 (34.4) | 53 (40.8) | |
| Sex - n (%) | .50 | |||
| Male | 166 (52.5) | 103 (55.4) | 63 (48.5) | |
| Female | 150 (47.5) | 83 (44.6) | 67 (51.5) | |
| Disease - n (%) | .85 | |||
| Acute myeloid leukemia | 132 (41.8) | 74 (39.8) | 58 (44.6) | |
| Myelodysplastic syndrome | 58 (18.4) | 34 (18.3) | 24 (18.5) | |
| Acute lymphoblastic leukemia | 48 (15.2) | 27 (14.5) | 21 (16.2) | |
| Lymphoma | 24 (7.6) | 16 (8.6) | 8 (6.2) | |
| Primary/secondary myelofibrosis | 22 (7.0) | 14 (7.5) | 8 (6.2) | |
| Others | 32 (10.1) | 21 (11.3) | 11 (8.5) | |
| Second transplant - n (%) | 21 (6.6) | 16 (8.6) | 5 (3.8) | .095 |
| Donor type - n (%) | .044 | |||
| Matched sibling | 66 (20.9) | 42 (22.6) | 24 (18.5) | |
| Matched unrelated | 155 (49.1) | 84 (45.2) | 71 (54.6) | |
| Mismatched unrelated | 42 (13.3) | 21 (11.3) | 21 (16.2) | |
| Haploidentical | 53 (16.8) | 39 (21.0) | 14 (10.8) | |
| Donor CMV serostatus - n (%) | .43 | |||
| Positive | 224 (70.9) | 135 (72.6) | 89 (68.5) | |
| Negative | 92 (29.1) | 51 (27.4) | 41 (31.5) | |
| Stem cell source - n (%) | .066∗ | |||
| Bone marrow | 141 (44.6) | 92 (49.5) | 49 (37.7) | |
| Peripheral blood stem cell | 171 (54.1) | 94 (50.5) | 77 (59.2) | |
| Cord blood | 4 (1.3) | 0 (0) | 4 (3.1) | |
| Conditioning regimen - n (%) | .56 | |||
| Myeloablative | 147 (46.5) | 84 (45.2) | 63 (48.5) | |
| Reduced intensity | 169 (53.5) | 102 (54.8) | 67 (51.5) | |
| Total body irradiation - n (%) | 62 (19.6) | 34 (18.3) | 28 (21.5) | .47 |
| GVHD prophylaxis - n (%) | .14 | |||
| Cyclosporin A + methotrexate | 229 (72.5) | 129 (69.4) | 100 (76.9) | |
| Cyclosporin A + MMF | 87 (27.5) | 57 (30.6) | 30 (23.1) | |
| In vivo T-cell depletion - n (%) | 219 (69.3) | 127 (68.3) | 92 (70.8) | .64 |
| Antithymocyte globulin | 155 (49.1) | 82 (44.1) | 73 (56.2) | |
| Post-transplant cyclophosphamide | 64 (20.3) | 45 (24.2) | 19 (14.6) | |
| CMV risk score - n (%) | .79 | |||
| Low-risk | 156 (49.4) | 93 (50.0) | 63 (48.5) | |
| High-risk | 160 (50.6) | 93 (50.0) | 67 (51.5) |
CMV, cytomegalovirus; GVHD, graft versus host disease; IQR, interquartile range; MMF, mycophenolate mofetil.
Excluding cord blood.